Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forepont Capital Partners is a global asset manager headquartered in New York, founded in 2017. The firm specializes in healthcare and life sciences investments, having initially commenced operations in 2011 by financing medical research in neurology. With a strong commitment to advancing healthcare innovation, Forepont has built a robust network of partnerships with physicians, researchers, and pharmaceutical companies, which enhances its investment and research initiatives. The firm operates under a unique philanthropy-investment hybrid model, where it funds basic research while simultaneously investing in startups that emerge from these scientific discoveries. This dual approach not only supports the development of groundbreaking medical technologies but also positions Forepont as a leader in the healthcare investment landscape. Although the specific fund size is not publicly disclosed, Forepont is recognized for its institutional-scale deployment, focusing on early-stage to growth equity investments. The firm has a notable presence in both North America and Europe, allowing it to tap into diverse markets and innovative healthcare solutions.
Forepont Capital Partners primarily invests in biotech, medtech, and e-health startups, with a strong emphasis on companies located in the United States and Europe. The firm targets investments at various stages, including pre-seed, seed, Series A, and Series B, with check sizes ranging from $1 million to $10 million. Forepont is particularly interested in startups that are approaching critical inflection points in their development, where scientific, technological, financial, and operational support can significantly enhance their performance. The firm evaluates potential investments based on a comprehensive understanding of the medical, human, financial, and ethical implications involved. By focusing on sectors such as rapid diagnostics, organ failure prevention, and innovative therapeutic approaches, Forepont aims to back companies that are not only technologically advanced but also address pressing healthcare challenges. This strategic focus allows Forepont to leverage its extensive network and expertise to foster the growth of its portfolio companies, ultimately contributing to advancements in healthcare and life sciences.
Forepont Capital Partners boasts a diverse portfolio of innovative companies across various sectors within healthcare and life sciences. Notable investments include a biotech firm dedicated to revolutionizing rapid diagnostics, a company utilizing artificial intelligence to prevent organ failure, and a pioneer in implantable neural interface technology. Additionally, the portfolio features a developer of a universal vaccine against pneumococcus, a firm specializing in active guidewires for endovascular access, and French innovators in rapid tests for infectious diseases. Other significant investments include a company exploring novel therapeutic approaches in the microbiome, a firm advancing biopharmaceutical manufacturing technologies, and a startup focused on creating new treatment options for women's health. This varied portfolio reflects Forepont's commitment to supporting groundbreaking innovations that have the potential to transform healthcare delivery and improve patient outcomes.
To pitch Forepont Capital Partners, founders should prepare a detailed pitch deck that outlines their business model, market opportunity, and technological innovations. While specific submission guidelines are not provided, it is advisable to reach out directly for more information on their preferred pitch format and process.
Recently, Forepont Capital Partners participated in a EUR 6 million Series A funding round for BCV in December 2023. This investment highlights Forepont's active role in supporting disruptive biotech and medtech startups, reinforcing its reputation as a leading venture capital firm in the healthcare sector.
Forepont Capital Partners invests in various stages, including pre-seed, seed, Seed+, Series A, Series A+, Series B, and growth equity. This broad range allows them to support startups at different points in their development journey.
To pitch Forepont Capital Partners, founders should prepare a comprehensive presentation that outlines their business model, market opportunity, and how their technology addresses a significant healthcare challenge. While specific submission guidelines are not provided, a well-structured pitch deck is essential.
Forepont Capital Partners primarily focuses on biotech, medtech, and e-health sectors. They are particularly interested in startups that are innovating in areas such as diagnostics, organ failure prevention, and therapeutic development.
The typical check size for investments made by Forepont Capital Partners ranges from $1 million to $10 million. This allows them to provide substantial support to their portfolio companies.
Forepont Capital Partners invests primarily in North America and Europe, leveraging their presence in these regions to identify and support innovative healthcare startups.
The application process for Forepont Capital Partners involves submitting a detailed pitch that highlights the startup's value proposition and market potential. Founders are encouraged to reach out directly for more specific guidance on their submission process.
Forepont Capital Partners offers extensive support to its portfolio companies, including scientific and technological guidance, operational expertise, and financial backing. Their partnerships with researchers and industry stakeholders enhance the growth and success of their investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.